RxDoctor Payments Data

Mark Passerman, DO

Family Medicine · Dwight, ILNPI 1851404313

Payments from drug & device makers

$960in general payments, 2019–2025

Across 37 payments — averaging $25.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$263
  • AstraZeneca$139
  • Amgen$108
  • Xeris Pharmaceuticals, Inc.$64
  • Novartis$55
  • Abbott$53
  • plus $278 from 11 others

What the payments were for

  • Food & beverage$94899%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$960 in reported general payments places this provider in the 70th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$119,674
Medicare patients
402
Services billed
1,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$68,984
OzempicSemaglutide56$62,276
TrulicityDulaglutide55$61,383
FarxigaDapagliflozin Propanediol49$47,372
RybelsusSemaglutide30$42,050
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$35,010
MyrbetriqMirabegron36$27,239
JardianceEmpagliflozin19$25,535
XareltoRivaroxaban31$24,811
Breo ElliptaFluticasone/Vilanterol31$15,289
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen367$10,478
Aripiprazole25$10,028
Tresiba Flextouch U-100Insulin Degludec13$9,974
NuedextaDextromethorphan Hbr/Quinidine12$9,585
Albuterol Sulfate HfaAlbuterol Sulfate325$8,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$263$104,32686 claims
Lilly USA, LLCTrulicity$13$61,38355 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$33$56,97087 claims
AstraZenecaFarxiga, Symbicort$139$55,29381 claims
Johnson & JohnsonXarelto$46$24,81131 claims
MerckDulera$18$4,44212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Dwight

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →